Which of the following accurately differentiates between guselkumab and tildrakizumab?
a. Guselkumab is a biologic targeting IL-17, while tildrakizumab is a biologic targeting IL-23.
b. Tildrakizumab is more strongly associated with gastrointestinal side effects compared with guselkumab.
c. Antidrug antibody reaction may occur with tildrakizumab but not with guselkumab.
d. Short-term efficacy of guselkumab may be higher than that of tildrakizumab for the management of severe plaque psoriasis.